Brought to you by 
Lion Biotechnologies licenses tumor cell therapy technologies from Moffitt Cancer Center
Jul 2014
Executive Summary
Lion Biotechnologies Inc. (cancer immunotherapies) licensed exclusive rights to two patent-pending tumor infiltrating lymphocyte (TIL) technologies from the University of South Florida’s H. Lee Moffitt Cancer Center & Research Institute. The license continues until the last patent related to the technologies expires, or 20 years, whichever comes first.
Deal Industry
-
Biotechnology
- Gene Therapy, Cell Therapy
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Alliance
- Includes Royalty or Profit Split Information
- R+D and Marketing-Licensing
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com